Flecainide
Antiarrhythmics, Class Ic
- Drug class
- Antiarrhythmics, Class Ic
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 17
Overview
Plain-language summary, compiled from the cited regulatory records
Flecainide is an antiarrhythmic medication belonging to Class Ic [1]. It is approved for the prevention of certain types of abnormal heart rhythms in patients who do not have structural heart disease [1].
Specifically, flecainide is indicated for the prevention of paroxysmal supraventricular tachycardias (PSVT), which include atrioventricular nodal reentrant tachycardia and atrioventricular reentrant tachycardia [1]. It is also used for other supraventricular tachycardias of unknown cause that are associated with disabling symptoms [1]. Additionally, flecainide is approved for the prevention of paroxysmal atrial fibrillation/flutter (PAF) when it causes disabling symptoms [1].
This medication is available under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 12 | May 15, 2026 |
| US United States | FDA | 3 | January 6, 2026 |
| CA Canada | Health Canada | 2 | March 22, 2025 |
GBUnited Kingdom· MHRA
12 products
Uses
Flecainide acetate is indicated for use in patients with the following arrhythmias: Severe symptomatic supraventricular arrhythmia AV nodal reciprocating tachycardia. Arrhythmias associated with the Wolff-Parkinson-White syndrome and similar conditions associated with the presence of accessory pathways.
Paroxysmal atrial fibrillation in patients with disabling symptoms after cardioversion. Patients with structural heart disease and/or impaired left ventricular function should be excluded because of the increased risk of pro-arrhythmic effects.
Arrhythmias of recent onset will respond more readily. Symptomatic sustained ventricular tachycardia. Premature ventricular contractions and/or non-sustained ventricular tachycardia which are causing disabling symptoms which have failed to respond to other forms of therapy or in which other treatments have not been tolerated.
Flecainide tablets can be used for the maintenance of normal rhythm following conversion by other means.
USUnited States· FDA
3 products
Uses
INDICATIONS AND USAGE
In patients without structural heart disease, flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms.
Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician, are life-threatening. Use of flecainide for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital.
The use of flecainide is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of flecainide, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks.
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Drug interactions
Known interactions involving Flecainide. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 423. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL045691096 · revised May 15, 2026
- [2]FDA DailyMed · 166aa9e4-3402-4e… · revised January 6, 2026 [PDF]
- [3]Health Canada (DPD) · 02534800 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.